Anti-viral photodynamic therapy in COVID-19 management: a novel approach in treating patients in early infection stages
| ISRCTN | ISRCTN10839729 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10839729 |
| Secondary identifying numbers | Covid2021001 |
- Submission date
- 27/04/2021
- Registration date
- 29/04/2021
- Last edited
- 29/04/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
COVID-19 is a condition caused by the coronavirus (called SARS-CoV-2) that was first identified in late 2019. This virus can infect the respiratory (breathing) system. Some people do not have symptoms but can carry the virus and pass it on to others. People who have developed the condition may develop a fever and/or a continuous cough among other symptoms. This can develop into pneumonia. Pneumonia is a chest infection where the small air pockets of the lungs, called alveoli, fill with liquid and make it more difficult to breathe.
After a temporary slowdown in summer 2020 infection numbers and death rates have been increasing again in recent months leading to various restrictions of social and economic life in many countries. The latest developments of new vaccinations seem to be promising; however, large-scale production and worldwide distribution logistics take time while questions such as longevity of immune protection, long-term side-effects etc are remaining unclear at this point. Furthermore, vaccination is a preventive approach and not a treatment for acutely infected patients. Treatments are still needed to help people with COVID-19 infection. The aim of this study is to find out whether photodynamic therapy (PDT) with riboflavin and a specially designed light treatment kit would be able to fill this gap by helping people in the early stages of infection. This may lead to relief for hospitals and intensive care stations.
Who can participate?
Acutely infected COVID-19 patients aged 10-90 from Gandhi hospital in Tehran
What does the study involve?
Participants are randomly allocated to receive either photodynamic therapy plus daily testing for 5 days or to receive conventional care plus testing. Viral load is measured at the start of the study and after 24, 48, 72, 96, 120 and 168 hours.
What are the possible benefits and risks of participating?
Possible benefits are lowering the viral load and improving the symptoms of Covid-19 patients. There are no significant risks or side effects to be expected according to safety measurements that have been done before.
Where is the study run from?
Gandhi Hospital (Iran)
When is the study starting and how long is it expected to run for?
September 2020 to February 2021
Who is funding the study?
Weber Medical (Germany)
Who is the main contact?
Dr. med. Michael Weber
robert.weber@webermedical.com
Contact information
Scientific
Sohnreystrasse 4
Lauenfoerde
37697
Germany
| Phone | +49 (0)5273367780 |
|---|---|
| robert.weber@webermedical.com |
Study information
| Study design | Interventional non-randomized study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | No participant information sheet available |
| Scientific title | Successful reduction of SARS-CoV-2 viral load by photodynamic therapy verified by quantitative PCR – a novel approach in treating patients in early infection stages |
| Study objectives | The objective of this study is to evaluate if Photodynamic Therapy (PDT) with riboflavin and a specially designed light treatment kit would be able to help people in the early stages of infection by reducing viral load and clinical symptoms. |
| Ethics approval(s) | No ethical approval required because of the emergency COVID-19 situation in Tehran/Iran in November 2020 |
| Health condition(s) or problem(s) studied | COVID-19 (SARS-CoV-2 infection) |
| Intervention | Patients are assigned in the sequence of hospital admission to two groups with 70 patients in the experiment (verum) group receiving daily Photodynamic Therapy and daily testing for 5 days and a control group receiving conventional care plus testing for 5 days. All patients in both groups had positive COVID-19 test results at the beginning of the study. They were in an early infection stage with mild symptoms like fever, dry cough, headache, hard breathing, fatigue etc. Quantitative PCR (QPCR) tests with Ct-viral load are performed on day 1, 2, 3, 4, 5 and 7 in the experiment group and on day 1, 3, 5 and 7 in the control group. |
| Intervention type | Mixed |
| Primary outcome measure | Viral load measured using the QPCR test (Ct value) at baseline, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours and 168 hours |
| Secondary outcome measures | Clinical symptoms measured using the visual analogue score (VAS) at baseline, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours and 168 hours |
| Overall study start date | 02/09/2020 |
| Completion date | 28/02/2021 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Mixed |
| Sex | Both |
| Target number of participants | 140 |
| Total final enrolment | 140 |
| Key inclusion criteria | 1. Men and women 2. Aged 10-90 years 3. Early stages of COVID-19 (SARS-CoV-2 infection) |
| Key exclusion criteria | 1. Late infection stages 2. Pregnant women 3. Children aged under 10 years |
| Date of first enrolment | 01/11/2020 |
| Date of final enrolment | 15/02/2021 |
Locations
Countries of recruitment
- Iran
Study participating centre
Tehran
1000
Iran
Sponsor information
Research organisation
Loensstr. 10
Lauenfoerde
37697
Germany
| Phone | +49 (0)52733677818 |
|---|---|
| info@isla-laser.org | |
| Website | isla-laser.org |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 01/05/2021 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Other |
| Publication and dissemination plan | Planned publication in a high-impact peer-reviewed journal |
| IPD sharing plan | The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication. |
Editorial Notes
29/04/2021: Trial's existence confirmed by Gandhi Hospital.
